Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostaglandin E1 in severe Raynaud's phenomenon.

B J Pardy, M C Hoare, H H Eastcott

    Surgery
    |December 1, 1982
    PubMed
    Summary

    Prostaglandin E1 (PGE1) significantly improved finger blood flow and healing in patients with severe Raynaud

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Restoration of a Popliteal Artery by a Frozen Arterial Homograft.

    Proceedings of the Royal Society of Medicine·2009
    Same author

    Late Rupture of Orlon Aortic Graft.

    Proceedings of the Royal Society of Medicine·2009
    Same author

    Autoimmune Thyroiditis with Raised I Uptake.

    Proceedings of the Royal Society of Medicine·2009
    Same author

    Strokes [Abridged].

    Proceedings of the Royal Society of Medicine·2009
    Same author

    The new operation codes: an improvement?

    Annals of the Royal College of Surgeons of England·2009
    Same author

    Prostate abscess presenting as priapism.

    International journal of clinical practice. Supplement·2005

    Area of Science:

    • Vascular Medicine
    • Pharmacology

    Background:

    • Severe Raynaud's phenomenon can lead to finger sepsis and necrosis.
    • Previous treatments like sympathectomy have limitations.

    Purpose of the Study:

    • To evaluate the efficacy of prostaglandin E1 (PGE1) in treating severe Raynaud's phenomenon with finger sepsis or necrosis.

    Main Methods:

    • Intravenous PGE1 administration for 72 hours in 21 patients.
    • Comparison with saline placebo.
    • Assessment of finger skin temperature, digital arterial flow, and pressure index.
    • Surgical debridement of necrotic tissue when necessary.

    Main Results:

    • PGE1 significantly improved digital arterial flow, finger skin temperature, and pressure index compared to placebo.
    • Symptomatic improvement observed in 12 of 13 patients with sepsis/necrosis (Group II).
    • No deterioration and successful healing of debrided fingers post-PGE1 treatment.

    Conclusions:

    • PGE1 is an effective treatment for acute exacerbations of finger sepsis and necrosis in severe Raynaud's phenomenon.
    • PGE1 offers a safe, repeatable alternative to sympathectomy with fewer side effects.
    • Nail bed removal can prevent recurrent sepsis and necrosis.

    Related Experiment Videos